Effect of probiotic yoghurt in patients with non-alcoholic fatty liver disease (NAFLD)

Comparing the effect of probiotic and conventional yoghurt consumption on metabolic status and serum hs-CRP level, leptin and paraoxonase 1 enzyme activity in patients with non-alcoholic fatty liver disease (NAFLD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201205293664N7

Enrollment

Registered

2012-06-17

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Other diseases of liver

Interventions

Intervention 1: Intervention group: 300 gr probiotic yoghurt daily. Intervention 2: Placebo group: 300 gr conventional yoghurt daily.

Intervention group: 300 gr probiotic yoghurt daily

Placebo group: 300 gr conventional yoghurt daily

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who agree to participate in the study; women aged 20-50 years (premenopausal) and in men 20-65 years; BMI range between 25 to 40 kg/ m2 and suffering from nonalcoholic fatty liver disease. Exclusion criteria: suffering from gastrointestinal disease, diabetes and rheumatoid arthritis; receiving antibiotics during the two weeks before and during the study; follow the diet and weight loss; receiving supplements of vitamins, antioxidants, fiber and omega-3 within 3 weeks before baseline and during the study; presence of pregnancy or lactation or menopause; taking contraceptive drugs; liver transplantation; alcohol intake; any cause of chronic liver disease other than NAFLD, such as testing positive for hepatitis B, hepatitis C and autoimmune hepatitis – Immune; history of cancer and treatment; performing a complete intravenous feeding; rapid weight loss; cut part of the intestine and gastropathy; drugs such as corticosteroids, amiodarone, tamoxifen, cyclins, perhexiline, methotrexate, aspirin and hydralazine; presence of inherited Hemochromatosis (transferrin saturation greater than 45%) and Wilson's disease; Cholestatic liver disease; advanced liver disease; heart failure; thyroid (abnormal TSH) and renal disease; gastric bypass surgery and cachexia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver Enzymes(ALT,AST). Timepoint: Baseline and at the end of intervention. Method of measurement: Autoanalyzer.;Total Cholesterol. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;Triglyceride. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: Baseline and at the end of intervention. Method of measurement: Friedewald Formula.;Insulin. Timepoint: Baseline and at the end of intervention. Method of measurement: ELIZA.;HOMA-IR. Timepoint: Baseline and at the end of intervention. Method of measurement: Formula.;Fasting Blood Sugar. Timepoint: Baseline and at the end of intervention. Method of measurement: spectrophotometry.;Malondialdehyde. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;HsCRP. Timepoint: Baseline and at the end of intervention. Method of measurement: immunotorbidometry.;Leptin. Timepoint: Baseline and at the end of intervention. Method of measurement: ELIZA.;Activity of PON1 Enzyme. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;AST/ALT. Timepoint: Baseline and at the end of intervention. Method of measurement: Formula.	—

Measure

Time frame

Liver Enzymes(ALT,AST). Timepoint: Baseline and at the end of intervention. Method of measurement: Autoanalyzer.;Total Cholesterol. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;Triglyceride. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;HDL. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: Baseline and at the end of intervention. Method of measurement: Friedewald Formula.;Insulin. Timepoint: Baseline and at the end of intervention. Method of measurement: ELIZA.;HOMA-IR. Timepoint: Baseline and at the end of intervention. Method of measurement: Formula.;Fasting Blood Sugar. Timepoint: Baseline and at the end of intervention. Method of measurement: spectrophotometry.;Malondialdehyde. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;HsCRP. Timepoint: Baseline and at the end of intervention. Method of measurement: immunotorbidometry.;Leptin. Timepoint: Baseline and at the end of intervention. Method of measurement: ELIZA.;Activity of PON1 Enzyme. Timepoint: Baseline and at the end of intervention. Method of measurement: Spectrophotometry.;AST/ALT. Timepoint: Baseline and at the end of intervention. Method of measurement: Formula.

—

Secondary

Measure	Time frame
Dietary Factors. Timepoint: Baseline and at the end of intervention. Method of measurement: 3-day 24h dietary recalls.;Body Mass Index. Timepoint: Baseline and at the end of intervention. Method of measurement: Formula.;Echogeneocity of liver tissue. Timepoint: Baseline and at the end of intervention. Method of measurement: Ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSafoora Nabavi

Tabriz University of Medical Sciences

safoora.nabavi@yahoo.com+98 918 372 9871

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026